Clinical Trials Logo
  1. Home
  2. Endometrial Cancer
  3. NCT05542940
  4. Details
NCT05542940 Clinical Trial

P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer

Endometrial Cancer Clinical Trial

Official title:
P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer and Its Relation With Disease Stages, Pathological Types and Grading

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05542940
Other study ID # SOKKARY9
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2020
Est. completion date August 31, 2022

Study information
Verified date September 2022
Source Alexandria University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objective: Calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types and grading. Patients and methods: 100 cases of endometrial cancer will be included in the study, recruited from Alexandria university hospital gyne-oncology unit. Surgical staging, histopathological examination and immunohistochemistry of p53 were done to all cases to calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types, grading. Keywords: P53 immunohistochemistry, endometrial cancer, clinicopathological relation.

Recruitment information / eligibility
Status Completed
Enrollment 100
Est. completion date August 31, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - endometrial cancer patients Exclusion Criteria: - patients unfit for surgery

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading

Locations
Country Name City State
Egypt Hossam Hassan El Sokkary Alexandria

Sponsors (1)
Lead Sponsor Collaborator
Hossam Hassan Aly Hassan El Sokkary

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary p53 immunohistochemistry Incidence of abnormal staining of p53 in endometrial cancer 1 month
Primary Relation of p53 abnormal staining with disease stages Relation of p53 abnormal staining with disease stages 1month
Primary Relation of p53 abnormal staining with disease pathological types Relation of p53 abnormal staining with disease pathological types 1 month
Primary Relation of p53 abnormal staining with disease pathological grades Relation of p53 abnormal staining with disease pathological grades 1 month
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05796518 - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors N/A
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Completed NCT03820024 - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback N/A
Active, not recruiting NCT05082025 - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Phase 2
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Recruiting NCT04569773 - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Not yet recruiting NCT05998798 - Revealing Engagement Patterns Among Endometrial Cancer Patients
Not yet recruiting NCT06073184 - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Phase 2
Not yet recruiting NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Phase 2
Terminated NCT02907073 - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Phase 1/Phase 2
Completed NCT02413606 - ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? N/A
Completed NCT02549989 - Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Phase 2